Rigel Pharmaceuticals RIGL EBITDA

EBITDA at other companies

AmgenAMGN

$4.63B+15.7%

Agios PharmaceuticalsAGIO

-$109.2M+13.2%

Zevra Therapeutics, Inc.ZVRA

$17.14M+125%

Gyre Therapeutics, Inc.GYRE

-$12.88M-946%

Opko HealthOPK

$15.44M+142%

Eton Pharmaceuticals, Inc.ETON

$3.55M+553%

FAQ

What is Rigel Pharmaceuticals's EBITDA?

Rigel Pharmaceuticals (RIGL) reported EBITDA of $12.48M in Q1 2026.

How has Rigel Pharmaceuticals's EBITDA changed year-over-year?

Rigel Pharmaceuticals's EBITDA decreased by 6.7% year-over-year, from $13.38M to $12.48M.

What is the long-term trend for Rigel Pharmaceuticals's EBITDA?

Over 4 years (2021 to 2025), Rigel Pharmaceuticals's EBITDA has grown at a 83.3% compound annual growth rate (CAGR), from -$11.33M to $127.88M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.